Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence
Looking at the top three goals of pre-launch and the role of digital scientific leaders and social media in launch excellence
By Ludivine Delattre and Stacy Vaughn
By Henry Skinner, Chief Executive Officer of the AMR Action Fund
By Jorg Taubel
By Danny Buckland
When all-inclusive isn’t an option, it’s an obligation
Investigating the EU regulatory hurdles that life sciences companies face as they seek to improve patient access to biosimilar therapy
While some errors are unforeseen, many can be prevented with better planning, coordination, communication and transparency in launch planning and implementation
Symptoms shared with more common diagnoses can make it more difficult to spot underlying rare diseases
With wide applicability and the many time and cost savings they can bring, robots have been steadily integrated into healthcare over the last decade
How COVID-19’s lasting legacy will reshape clinical cancer research
To ensure the successful discovery and development of new dementia therapies, key gaps in the field need to be addressed
How the pandemic is forcing a fresh focus on the human touch and fresh thinking about engagement
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story